Novartis v Hospira — what do innovators and generics need to know?
In a robust decision handed down by the English Court of Appeal, Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’s patents having been declared invalid by the English High Court.
The revocation proceedings are expected to reach the Court of Appeal some time in autumn 2013. Until then, Novartis is able to enjoy market exclusivity on its proprietary zoledronic acid product, Aclasta.
The Court of Appeal judgment represents a significant victory for Novartis and other innovators. In this e-alert, Allen & Overy discusses how this decision affects innovators and generic companies alike, as well as the practical steps that parties should consider prior to the launch of a generic product…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
The ITC has reaffirmed its power to ban electronic transmissions from the US where those transmissions infringe an intellectual property right or are otherwise based on an unfair trade practice.
A new French law, the ‘Law to recapture the real economy’ (‘Loi visant à reconquérir l’économie réelle’ or ‘Loi Florange’), was made on 1 April 2014.
Analysis from The Lawyer
Imagine you’re the general counsel of London-based private equity investor BC Partners. You’re sipping on your coffee, hashing out the details of your imminent £382m investment into UK-based business publishing company Mergermarket.
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe